Results 11 to 20 of about 38,007 (143)

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine [PDF]

Cell, 2021
Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was introduced in the United Kingdom to accelerate population coverage with a single dose. At this time, trial data were lacking, and we addressed this in a study of United Kingdom healthcare workers.
Stephanie Longet, David Eyre, Susan Hopkins   +2 more
exaly   +6 more sources

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma. [PDF]

Clin Pharmacol Ther
Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing regimens in a real‐world setting are limited.
Malmberg R, Hofman MM, Ashad F, Daloul A, Oosterveld S, Basak EA, Oomen-de Hoop E, van der Veldt AAM, Joosse A, van Leeuwen RWF, Mathijssen RHJ.   +10 more
europepmc   +4 more sources

Optimizing gentamicin conventional and extended interval dosing in neonates using Monte Carlo simulation – a retrospective study [PDF]

BMC Pediatrics, 2019
Background Although aminoglycosides are routinely used in neonates, controversy exists regarding empiric dosing regimens. The objectives were to determine gentamicin pharmacokinetics in neonates, and develop initial mg/kg dosing recommendations that ...
Monique Bergenwall, Sandra A. N. Walker, Marion Elligsen, Dolores C. Iaboni, Carla Findlater, Winnie Seto, Eugene Ng   +6 more
doaj   +2 more sources

Extended interval dosing of natalizumab: a two-center, 7-year experience [PDF]

Therapeutic Advances in Neurological Disorders, 2014
Background: The enthusiasm for natalizumab, a highly efficacious agent in the treatment of multiple sclerosis (MS), has been tempered by the risks of progressive multifocal leukoencephalopathy associated with its use, and strategies to minimize those ...
Roberto Bomprezzi, Siddharama Pawate
doaj   +2 more sources

Safety and clinical outcomes of pembrolizumab standard-interval dosing versus extended-interval dosing in patients with breast cancer. [PDF]

Oncologist
Abstract Introduction Extended-interval (EI) dosing of pembrolizumab (400 mg IV every 6 weeks) was approved across all solid tumors based on pharmacokinetic modeling and exposure-response analyses.
LeVee A, Kordic A, Ruel N, Mortimer J, Kang I, McArthur H, Lechner MG, Tsai K.   +7 more
europepmc   +3 more sources

Extended-Interval Dosing of Aminoglycosides in Pediatrics: A Narrative Review

Journal of Pediatrics Review, 2015
Aminoglycosides (AGs) are frequently used in pediatric settings, especially for empiric treatment of early-onset neonatal sepsis. Although AGs are used for several decades, the optimum method of administration and their dosing schemes needs more ...
Ebrahim Salehifar, Mohammad Reza Rafati
doaj   +3 more sources

Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic? [PDF]

Frontiers in Oncology, 2020
Patients with lung cancer are particularly vulnerable to complications from coronavirus disease-2019 (COVID-19). Recurrent hospital visits and hospital admission are potential risk factors for acquiring infection with its causative pathogen, severe acute
Kartik Sehgal, Kartik Sehgal, Daniel B. Costa, Deepa Rangachari   +3 more
doaj   +2 more sources

Extended interval dosing of natalizumab: More evidence in support. [PDF]

Neurotherapeutics
Toljan K, Conway DS.
europepmc   +3 more sources

Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic [PDF]

Neurotherapeutics, 2022
Emanuele D'Amico, Carlo Avolio, Aurora Zanghì   +2 more
exaly   +2 more sources

Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every‐4‐Week Dosing to Extended‐Interval Dosing [PDF]

Journal of Clinical Pharmacology, 2021
Chang I, Muralidharan KK, Campbell N, Ho PR.   +3 more
exaly   +2 more sources